Heart Failure: Global Drug Forecast and Market Analysis to 2028

1.1 List of Tables
1.2 List of Figures

2.1 The HF Market Will Exhibit Strong Growth Between 2018 and 2028
2.2 Label Expansions of Anti-Diabetic Drugs Will Fuel Market Growth
2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline
2.4 Farxiga Will Dominate the Branded HF Market
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers/Targets of Interest
4.2 Classification or Staging Systems
4.3 Prognosis

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF
5.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF by EF
5.4.4 Forecast Assumptions and Methods: Acute Hospitalizations
5.4.5 Forecast Assumptions and Methods: Acute Hospitalizations by Worsening CHF, Advanced HF, and De Novo HF
5.4.6 Forecast Assumptions and Methods: Hospital Length of Stay
5.4.7 Forecast Assumptions and Methods: Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
5.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF
5.4.9 Diagnosed Prevalent Cases of CHF by EF
5.4.10 Diagnosed Prevalent Cases of CHF by NYHA Classes
5.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages
5.5 Epidemiological Forecast for Heart Failure (2018-2028)
5.5.1 Diagnosed Incident Cases of HF
5.5.2 Age-Specific Diagnosed Incident Cases of HF
5.5.3 Sex-Specific Diagnosed Incident Cases of HF
5.5.4 Diagnosed Incident Cases of HF by EF
5.5.5 AHF Hospitalizations
5.5.6 Hospital Length of Stay for AHF Hospitalization
5.5.7 Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
5.5.8 Diagnosed Prevalent Cases of CHF
5.5.9 Diagnosed Prevalent Cases of CHF by EF
5.5.10 Age-Specific Diagnosed Prevalent Cases of CHF
5.5.11 Sex-Specific Diagnosed Prevalent Cases of CHF
5.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class
5.5.13 Diagnosed Prevalent Cases of CHF with PEF by NYHA Class
5.5.14 Diagnosed Prevalent Cases of CHF with REF by NYHA Class
5.5.15 Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 5EU
6.5 Japan
6.6 China

7.1 Overview

Table 1: Heart Failure: Key Metrics in the 8MM
Table 2: Types of Chronic HF
Table 3: Causes of HF
Table 4: Compensatory Mechanisms in HF Patients
Table 5: Symptoms of Heart Failure
Table 6: Key Diagnostic and Prognostic Biomarkers in HF
Table 7: A Comparison of Two HF Classification Systems
Table 8: Common Factors that Precipitate AHF
Table 9: HF Treatment Guidelines Most Commonly Adhered to by Physicians in the 8MM
Table 10: Chronic HF-REF Medications Most Commonly Used in the 8MM
Table 11: Country Profile - US
Table 12: Country Profile - 5EU
Table 13: Country Profile - Japan
Table 14: Country Profile - China
Table 15: Leading Treatments for HF
Table 16: Amgen’s HF Portfolio Assessment, 2019
Table 17: Bayer’s HF Portfolio Assessment, 2019
Table 18: Bristol-Myers Squibb HF Portfolio Assessment, 2019
Table 19: Servier’s HF Portfolio Assessment, 2019
Table 20: Novartis’ Disease Portfolio Assessment, 2019
Table 21: Zensun’s Disease Portfolio Assessment, 2019
Table 22: AstraZeneca’s Disease Portfolio Assessment, 2019
Table 23: Lexicon’s Disease Portfolio Assessment, 2019
Table 24: Heart Failure Market - Global Drivers and Barriers, 2018-2028
Table 25: Key Events Impacting Sales for HF in the US, 2018-2028
Table 26: HF Market - Global Drivers and Barriers in the US, 2018-2028
Table 27: Key Events Impacting Sales for Heart Failure in the 5EU, 2018-2028
Table 28: Heart Failure Market - Global Drivers and Barriers in the 5EU, 2018-2028
Table 29: Key Events Impacting Sales for Heart Failure in Japan, 2018-2028
Table 30: Heart Failure Market - Global Drivers and Barriers in Japan, 2018-2028
Table 31: Key Events Impacting Sales for Heart Failure in China, 2018-2028
Table 32: Heart Failure Market - Global Drivers and Barriers in China, 2018-2028
Table 33: Key Historical and Projected Launch Dates for HF
Table 34: Key Historical and Projected Patent Expiry Dates for Heart Failure
Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales for Heart Failure by Country, 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in Heart Failure During the Forecast Period
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2018-2028
Figure 4: Changes in Cardiac Structure in HF
Figure 5: 8MM, Sources Used to Forecast Hospital Length of Stay for AHF Hospitalization
Figure 6: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF
Figure 7: 8MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class
Figure 8: 8MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N, 2018
Figure 9: 8MM, Sex-Specific Diagnosed Incident Cases of HF, All Ages, N, 2018
Figure 10: 8MM, Diagnosed Incident Cases of HF by EF, Both Sexes, All Ages, N, 2018
Figure 11: 8MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, All Ages, N, 2018
Figure 12: 8MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, All Ages, N, 2018
Figure 13: 8MM, Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification, Both Sexes, All Ages, N, 2018
Figure 14: Diagnostic Algorithm for Chronic HF
Figure 15: Diagnostic Algorithm for Acute HF
Figure 16: HF based on the ACCF/AHA staging system
Figure 17: Classification of Acute HF Patients
Figure 18: Management of Acute HF Patients
Figure 19: Unmet Needs and Opportunities in Heart Failure
Figure 20: Overview of the Development Pipeline in Heart Failure
Figure 21: Competitive Assessment of Late-Stage Pipeline Agents in Chronic and Post-Acute Heart Failure, 2018-2028
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in Acute Heart Failure, 2018-2028
Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that the Publisher Expects to Be Licensed for HF in the 8MM During the Forecast Period
Figure 24: Company Portfolio Gap Analysis in Chronic HF, 2018-2028
Figure 25: Company Portfolio Gap Analysis in Acute Heart Failure, 2018-2028
Figure 26: Global Sales for Chronic HF by Country, 2018 and 2028
Figure 27: Global Sales for Acute HF by Country, 2018 and 2028
Figure 28: Sales for Chronic HF by Drug Class in the US, 2018 and 2028
Figure 29: Sales for Chronic HF by Drug Class in the 5EU, 2018 and 2028
Figure 30: Sales for Chronic HF by Drug Class in Japan, 2018 and 2028
Figure 31: Sales for Chronic HF by Drug Class in China, 2018 and 2028